Rutella Lab

Haematologist and Scientist

[Rutella Lab @LabRutella]

https://t.co/Zp9qMhLBer

[AML Hub @AML_Hub]

CONGRESS | #ASH23 | Sergio Rutella,
@TrentUni shares data on W-NK, concluding that W-NK cells are effective against AML cells under culture conditions to mimic hypoxia and immunosuppressive TME. W-NK is also observed to persist in BM tissues, to control AML in vivo. #AMLsm #leusm

[Myeloid/Lymphoid Malignancies Symposium @BcmHem]

Immunogenomic landscape of p53 AML. Sergio Rutella, M.D., Ph.D., Nottingham University, UK. April 26th, Genomic Workshop &Hem Malig symposium. Georgetown MedStar Unv. hospital. Register https://t.co/1idA1ogFpe. @ASH_hematology @LombardiCancer @BCMCancerCenter @leukaemielabor

[Myeloid/Lymphoid Malignancies Symposium @BcmHem]

Farhad Ravandi, M.D., AML MRD optimization before BMT, MD Anderson CC. April 27th, 10:50 am. Goldberg auditorium, MGHU. Register: https://t.co/1idA1ogFpe @LombardiCancer @BCMCancerCenter @aamdsif @LLSusa @leukaemielabor @ASH_hematology @SocietyofHemOnc @HMHNewJersey

[The Lancet Haematology @TheLancetHaem]

#EBMT21 Leo Luznik on the results of the BMT CTN 1301 trial comparing calcineurin inhibitor-free GVHD prophylaxis in HCT recipients who received myeloablative conditioning & had HLA-matched donors #bmtsm (2/2)

[The Lancet Haematology @TheLancetHaem]

#EBMT21 Leo Luznik on the results of the BMT CTN 1301 trial comparing calcineurin inhibitor-free GVHD prophylaxis in HCT recipients who received myeloablative conditioning & had HLA-matched donors #bmtsm (1/2)

[Rutella Lab @LabRutella]

Escape from T-cell targeting immunotherapies in acute myeloid leukemia https://t.co/rUxywuadko

[Rutella Lab @LabRutella]

Escape from T-cell targeting immunotherapies in acute myeloid leukemia https://t.co/rUxywuadko

[Rutella Lab @LabRutella]

Check this out!
Closing date: 30th June 2023. https://t.co/TG609XLQYJ

[Rutella Lab @LabRutella]

Open PhD position in my lab. Check it out!

#phdstudent
#phd
#immunooncology
#immunotherapy
#ash_hematology
#cancerresearch https://t.co/PJ3zO7RchA

[Rutella Lab @LabRutella]

I am hiring!

Just reach out to discuss, if you think you have the right skills and expertise.

#hiring
#ash_hematology
#immunology
#immunotherapy https://t.co/pqeFgEUTWc

[Rutella Lab @LabRutella]

Great to see very broad coverage of our AML work and an Altmetric score of 1,174!

#ash_hematology
#ash22
#immunotherapy
#immunooncology
#nottinghamtrentuniversity https://t.co/7tZwXeBBp8

[Rutella Lab @LabRutella]

#bsh_haematology
#ash_hematology
#ash22 https://t.co/KM3gHZB1nv

[Rutella Lab @LabRutella]

Fighting aggressive blood cancer ages and exhausts immune cells, study suggests https://t.co/NRAMTew9B0

[Rutella Lab @LabRutella]

Our T-cell dysfunction/senescence paper is finally out!

#ASH22
@ash_hematology https://t.co/pugm3VJ6RH

[Rutella Lab @LabRutella]

Signatures of immune dysfunction predict outcomes and define checkpoint blockade-unresponsive microenvironments in … https://t.co/D7zLnsmCc0

[Rutella Lab @LabRutella]

ESMO Congress 2022: LIVE Plus Prof. Solange Peters, ESMO President 2020-... https://t.co/hmft20i4Px via @YouTube

[Rutella Lab @LabRutella]

Why the party is over for Britain’s Research Excellence Framework https://t.co/Xx4NP7UDBZ

[Rutella Lab @LabRutella]

Research Fellow - Nottingham Trent University https://t.co/IN6R3USR60

[Rutella Lab @LabRutella]

Signatures of immune senescence predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia https://t.co/KEfROl2Xc6

[ESMO - Eur. Oncology @myESMO]

#ESMOImmuno21: Your chance to help us shape the future of immuno-oncology. Watch Kevin Harrington explain why you can’t miss this event and register to participate online.

👉 https://t.co/DirpgRHVEd

#immunooncology #immunotherapy #cancerresearch #immunonc